Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer

Cancer Research

Volumn 74, Issue 9, 2014, Pages 2617-2629

  Nagalingam, Arumugam ^a   Kuppusamy, Panjamurthy ^b   Singh, Shivendra V ^c   Sharma, Dipali ^a   Saxena, Neeraj K ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DEATH RECEPTOR 5; ETOPOSIDE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; S6 KINASE; TRANSCRIPTION FACTOR ELK 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE MAMMARY TUMOR ONCOVIRUS; PRIORITY JOURNAL; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL NUCLEUS; CELL SURVIVAL; ETS-DOMAIN PROTEIN ELK-1; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; TRANSCRIPTION FACTOR CHOP; TUMOR BURDEN; WITHANOLIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900027779     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2081     Document Type: Article

References (50)

1. Qurishi Y, Hamid A, Majeed R, Hussain A, Qazi AK, Ahmed M, et al. Interaction of natural products with cell survival and signaling pathways in the biochemical elucidation of drug targets in cancer. Future Oncol 2011;7:1007-21.
2. Ali R, Mirza Z, Ashraf GM, Kamal MA, Ansari SA, Damanhouri GA, et al. New anticancer agents: recent developments in tumor therapy. Anticancer Res 2012;32:2999-3005.
3. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazon J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules 2009;14:2373-93.
4. Vanden Berghe W, Sabbe L, Kaileh M, Haegeman G, Heyninck K. Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol 2012;84:1282-91.
5. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 2000;5:334-46. (Pubitemid 30660827)
6. Misra L, Mishra P, Pandey A, Sangwan RS, Sangwan NS, Tuli R. Withanolides from Withania somnifera roots. Phytochemistry 2008;69: 1000-4. (Pubitemid 351232964)
7. Chaurasiya ND, Uniyal GC, Lal P, Misra L, Sangwan NS, Tuli R, et al. Analysis of withanolides in root and leaf of Withania somnifera byHPLC with photodiode array and evaporative light scattering detection. Phytochem Anal 2008;19:148-54. (Pubitemid 351425316)
8. Stan SD, Hahm ER, Warin R, Singh SV. Withaferin A causes FOXO3aand Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 2008;68:7661-9.
9. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4- dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 2007;67:246-53. (Pubitemid 46142781)
10. Oh JH, Kwon TK. Withaferin A inhibits tumor necrosis factor-alphainduced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol 2009;9:614-9.
11. Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA, Shiva SS, et al. Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevantmouse model. J Natl Cancer Inst 2013;105:1111-22.
12. Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS ONE 2011;6: e23354.
13. Lee J, Hahm ER, Singh SV. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis 2010;31:1991-8.
14. Lee J, Sehrawat A, Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat 2012;136:45-56.
15. Grover A, Shandilya A, Punetha A, Bisaria VS, Sundar D. Inhibition of the NEMO/IKKbeta association complex formation, a novel mechanism associated with the NF-kappaB activation suppression by Withania somnifera's key metabolite withaferin A. BMC Genomics 2010;11 Suppl 4:S25.
16. Ndlovu MN, Van Lint C, Van Wesemael K, Callebert P, Chalbos D, Haegeman G, et al. Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol Cell Biol 2009;29:5488-504.
17. Munagala R, Kausar H, Munjal C, Gupta RC. Withaferin A induces p53- dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 2011;32:1697-705.
18. Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, et al. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics 2011;12 Suppl 1:S30.
19. Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, et al. Withaferin A inhibits breast cancer invasion and metastasis at subcytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer 2011;129:2744-55.
20. Falsey RR, Marron MT, Gunaherath GM, Shirahatti N, Mahadevan D, Gunatilaka AA, et al. Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2006;2: 33-8.
21. Le NT, Heo KS, Takei Y, Lee H,WooCH, Chang E, et al.Acrucial role for p90RSK-mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and atherosclerosis. Circulation 2013;127:486-99.
22. Yang SH, Jaffray E, Hay RT, Sharrocks AD. Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell 2003;12:63-74. (Pubitemid 36945037)
23. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, et al. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer 2011;18:413-28.
24. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res 2012;14:R35.
25. Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK, et al. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis 2012;33:918-30.
26. Saxena NK, Vertino PM, Anania FA, Sharma D. leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 2007;282:13316-25. (Pubitemid 47100545)
27. Sharma D, Fondell JD. Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci U S A 2002;99:7934-9. (Pubitemid 34650983)
28. Danson S, Dean E, Dive C, Ranson M. IAPs as a target for anticancer therapy. Curr Cancer Drug Targets 2007;7:785-94.
29. Xu C, Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, et al. High survivinmRNAexpression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. Breast Cancer. 2012 Sep 12. [Epub ahead of print].
30. Zhang Y, Zhu J, Tang Y, Li F, Zhou H, Peng B, et al. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol 2011; 6:49.
31. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst 2011;103:1656-64.
32. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, et al. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2012;135: 619-27.
33. Romeo Y, Roux PP. Paving the way for targeting RSK in cancer. Expert Opin Ther Targets 2011;15:5-9.
34. Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J 2012;441:553-69.
35. Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, et al. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 2007;26:683-700. (Pubitemid 46204248)
36. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERKinduced cell death-apoptosis, autophagy, and senescence. FEBS J 2010;277:2-21.
37. Shao N, Chai Y, Cui JQ, Wang N, Aysola K, Reddy ES, et al. Induction of apoptosis by Elk-1 and δElk-1 proteins. Oncogene 1998;17: 527-32. (Pubitemid 28395918)
38. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995;14:951-62.
39. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004;11:381-9. (Pubitemid 38489416)
40. Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008;7:163-73. (Pubitemid 351590418)
41. Lee TJ, Um HJ, Min do S, Park JW, Choi KS, Kwon TK. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen speciesmediated upregulation of death receptor 5 and downregulation of c-FLIP. Free Radic Biol Med 2009;46:1639-49.
42. Oh YT, Yue P, Zhou W, Balko JM, Black EP, Owonikoko TK, et al. Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through coactivation of ERK and JNK signaling. J Biol Chem 2012;287:257-67.
43. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G, t al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005;25:5404-16. (Pubitemid 40853578)
44. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 2010; 22:837-44.
45. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 2008;13:4258-75.
46. Wang A, Rud J, Olson CM Jr, Anguita J, Osborne BA. Phosphorylation of Nur77 by the MEK-ERK-RSK cascade induces mitochondrial translocation and apoptosis in T cells. J Immunol 2009;183:3268-77.
47. den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, et al. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 2013;332:194-201.
48. Zhuang S, Schnellmann RG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 2006;319:991-7.
49. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. Cisplatininduced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 2004;287:F543-9.
50. Hahm ER, Lee J, Singh SV. Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction by withaferin A in human breast cancer cells. Mol Carcinog. 2013 Sep 2. [Epub ahead of print].